Neurocrine Biosciences
NBIX
$75.35
Share price
4.00%
Change (1 day)
-34.61%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Market capitalization of Neurocrine Biosciences (NBIX)
Market cap: $7.14 Billion
As of January 2022 Neurocrine Biosciences has a market cap of $7.14 Billion. This makes Neurocrine Biosciences the world's 1890th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth.
Market cap history of Neurocrine Biosciences from 2001 to 2022
| Year | Market cap | Change |
|---|---|---|
| 2022 | $7.12 B | -11.74% |
| 2021 | $8.07 B | -9.86% |
| 2020 | $8.95 B | -9.71% |
| 2019 | $9.91 B | 52.97% |
| 2018 | $6.48 B | -5.57% |
| 2017 | $6.86 B | 104.23% |
| 2016 | $3.36 B | -31.11% |
| 2015 | $4.87 B | 185.67% |
| 2014 | $1.70 B | 171.56% |
| 2013 | $0.62 B | 26.57% |
| 2012 | $0.49 B | 5.82% |
| 2011 | $0.46 B | 12.02% |
| 2010 | $0.41 B | 250.42% |
| 2009 | $0.11 B | -3.12% |
| 2008 | $0.12 B | -28.92% |
| 2007 | $0.17 B | -56.01% |
| 2006 | $0.39 B | -83.04% |
| 2005 | $2.32 B | 29.33% |
| 2004 | $1.80 B | -6.48% |
| 2003 | $1.92 B | 37.56% |
| 2002 | $1.40 B | -10.09% |
| 2001 | $1.55 B |
End of Day market cap according to different sources
On Jan 27th, 2022 the market cap of Neurocrine Biosciences was reported to be:
$6.87 Billion
$6.87 Billion
$6.87 Billion
$6.90 Billion
$6.86 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap difference | Country |
|---|---|---|---|
 Pfizer PFE | $303.93 B | 4,152.12% | 🇺🇸 USA |
 AbbVie ABBV | $240.69 B | 3,267.46% | 🇺🇸 USA |
 Eli Lilly LLY | $229.98 B | 3,117.59% | 🇺🇸 USA |
 Repligen
RGEN | $10.27 B | 43.80% | 🇺🇸 USA |
 Athersys ATHX | $0.19 B | -97.32% | 🇺🇸 USA |
 Palatin Technologies PTN | $0.08 B | -98.75% | 🇺🇸 USA |
 Royalty Pharma RPRX | $16.65 B | 132.97% | 🇬🇧 UK |